RBC Capital Maintains Outperform on Krystal Biotech, Lowers Price Target to $375
Benzinga Newsdesk 6 hours ago
Analyst RatingsNewsPrice Target
RBC Capital analyst Lisa Walter maintains Krystal Biotech (NASDAQ:KRYS) with a Outperform and lowers the price target from $400 to $375.
RBC Capital analyst Lisa Walter maintains Krystal Biotech (NASDAQ:KRYS) with a Outperform and lowers the price target from $400 to $375.